In the Summer 2018 edition of the Royal College of Psychiatrist’s magazine, I N S I G H T, Professor David Baldwin, Chair of the College Psychopharmacology Committee gives advice on off-label prescribing:
The full article can be read here.
The following is an extract:
I would have expected this perspective, by a paid opinion leader and Chair of the Royal College of Psychiatrists Psychopharmacology Committee, to include full details of any potential declarations of competing interests. However, it did not.
Here then, are some of the declarations of competing interest that Professor Baldwin has given in the course of his career [it is likely that this list is not complete as there is no central register in the UK and there is no formal regulation of competing interests]: